Genmab — Juli 2024
-
-
Ja okay aktiesplit giver selvfølgelig en forskel men hvis Genmab kommer ind på en andenplads siden 2011 ud af C25 er det også fint nok for det er meget få der er 100% i Novo så hvis man har haft no 1 og no 2 siden 2011 vil det være det optilale i.f.t hvis man var 100% i Novo . Tror stadig der er mere potentiale i Genmab i.f.t Novo p,t og det har vi da også set her i juli.
-
Der er ingen hage ved 1900, bortset fra det runde tal.
-
another small epco trial - Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab https://www.clinicaltrials.gov/study/NCT06447376
-
Another Epkinly lymphoma combo goes pivotal https://www.oncologypipeline.com/apexonco/another-epkinly-lymphoma-combo-goes-pivotal
-
Tisotumab vedotin effective in recurrent cervical cancer - article in Nature, can't read it all,
but anyway.. https://www.nature.com/articles/s41571-024-00929-4 -
ESMO 2024 preview – conjugates in the spotlight https://www.oncologypipeline.com/apexonco/node/734 rinatabart
-
Epcoritamab vs SoC (SCHOLAR-5 cohort) in patients with R/R FL https://www.youtube.com/watch?v=SQgjUgIJU4E
-
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer https://www.targetedonc.com/view/tisotumab-vedotin-continues-to-show-survival-benefits-in-recurrent-cervical-cancer
-
Thanks E L.
-
from the Morningstart report on Novartis: several other drugs continue to post rapid gains. In particular, multiple
sclerosis drug Kesimpta (up 65%) holds the potential to exceed management's peak annual sales
guidance of $4 billion based on leading efficacy and convenient dosing -
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I https://www.geneonline.com/topo-1-and-frα-key-focus-areas-and-major-collaborations-in-adc-research-part-i/
-
Genmab i teknisk udbrud op gennem 50 dages MA, plus 12 % på tre uger https://ugebrev.dk/flashnews/genmab-i-teknisk-udbrud-op-gennem-50-dages-ma-plus-12-paa-tre-uger/
Men selvfølgelig tilfreds MA50 til en start.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind